Role of phospholipase C and phospholipase A2 in the nitric oxide- independent vasodilator effect of bradykinin in the rat perfused heart

D Fulton, JC McGiff and J Quilley

Department of Pharmacology, New York Medical College, Valhalla, USA.

The cytochrome P450-dependent component of the coronary vasodilator action of bradykinin which requires activation of K+ channels was examined in terms of the contribution of phospholipases in the rat Langendorff heart preparation. This component was isolated by inhibition of nitric oxide synthase with nitroarginine and cyclooxygenase with indomethacin, neither of which affects the coronary vasodilator action of bradykinin. However, nitroarginine elevated coronary perfusion pressure from approximately 40 to 130 mm Hg. The phospholipase C inhibitor, U73122 1-(6-((17 beta-3-methoxyestra- 1,3,5(10)-trien-17-yl) amino)hexyl)-1H-pyrrole-2,5-dione, reduced coronary vasodilator responses to bradykinin by greater than 80%. U73122 also diminished the coronary vasodilator action of cromakalim which activates ATP-sensitive K+ channels. The maleimide moiety of U73122 that has the capacity to affect K+ channels inhibited cromakalim- induced coronary vasodilation, but did not affect that to bradykinin. Inhibition of diacylglycerol lipase with RHC 80267 1,6-bis- (cyclohexyloximinocarbonylamino)-hexane was without an overall effect on coronary vasodilator responses to bradykinin. The cytosolic phospholipase A2 inhibitor, AACOCF3 arachidonyl trifluoromethyl ketone, decreased responses to bradykinin by up to 90% whereas inhibitors of the secretory form of phospholipase A2 oleyloxyethyl phosphorylcholine and ONO-RS-082 2-(p-amylcinnamoyl)amino-4-chlorobenzoic acid were less effective than either AACOCF3 or U73122. The phospholipase inhibitors demonstrated selectivity as they did not affect the coronary vasodilator responses to nitroprusside. We obtained additional evidence for the antiphospholipase activity of the inhibitors by demonstrating their capacity to suppress bradykinin-stimulated increases in the release of prostacyclin, measured as 6-keto prostaglandin F1 alpha. The phospholipase inhibitors did not affect cyclooxygenase activity as the ability of arachidonic acid to stimulate prostaglandin formation was unimpaired. These results indicate that the coronary vasodilator action of bradykinin is linked to the activities of both phospholipase C and A2.

Volume 278, Issue 2, pp. 518-526, 08/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				M. A. Carroll, A. B. Doumad, J. Li, M. K. Cheng, J. R. Falck, and J. C. McGiff Adenosine2A receptor vasodilation of rat preglomerular microvessels is mediated by EETs that activate the cAMP/PKA pathway Am J Physiol Renal Physiol, July 1, 2006; 291(1): F155 - F161. [Abstract] [Full Text] [PDF]

				Y.-J. Chen, H. Jiang, and J. Quilley The Nitric Oxide- and Prostaglandin-Independent Component of the Renal Vasodilator Effect of Thimerosal Is Mediated by Epoxyeicosatrienoic Acids J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1292 - 1298. [Abstract] [Full Text] [PDF]

				I. Szokodi, P. Tavi, G. Foldes, S. Voutilainen-Myllyla, M. Ilves, H. Tokola, S. Pikkarainen, J. Piuhola, J. Rysa, M. Toth, et al. Apelin, the Novel Endogenous Ligand of the Orphan Receptor APJ, Regulates Cardiac Contractility Circ. Res., September 6, 2002; 91(5): 434 - 440. [Abstract] [Full Text] [PDF]

				C. L. Oltman, N. L. Kane, J. L. Fudge, N. L. Weintraub, and K. C. Dellsperger Endothelium-derived hyperpolarizing factor in coronary microcirculation: responses to arachidonic acid Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1553 - H1560. [Abstract] [Full Text] [PDF]

				Y. Qiu and J. Quilley Vascular effects of arachidonic acid in the rat perfused heart: role of the endothelium, cyclooxygenase, cytochrome P450, and K+ channels J. Lipid Res., December 1, 1999; 40(12): 2177 - 2184. [Abstract] [Full Text] [PDF]

				I. R. Hutcheson, A. T. Chaytor, W. H. Evans, and T. M. Griffith Nitric Oxide–Independent Relaxations to Acetylcholine and A23187 Involve Different Routes of Heterocellular Communication : Role of Gap Junctions and Phospholipase A2 Circ. Res., January 22, 1999; 84(1): 53 - 63. [Abstract] [Full Text] [PDF]

				D. Fulton, J. C. Mcgiff, and J. Quilley Pharmacological Evaluation of an Epoxide as the Putative Hyperpolarizing Factor Mediating the Nitric Oxide-Independent Vasodilator Effect of Bradykinin in the Rat Heart J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 497 - 503. [Abstract] [Full Text]

				D. Fulton and J. Quilley Evidence against Anandamide as the Hyperpolarizing Factor Mediating the Nitric Oxide-Independent Coronary Vasodilator Effect of Bradykinin in the Rat J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1146 - 1151. [Abstract] [Full Text]

				D. Fulton, J. R. Falck, J. C. McGiff, M. A. Carroll, and J. Quilley A method for the determination of 5,6-EET using the lactone as an intermediate in the formation of the diol J. Lipid Res., August 1, 1998; 39(8): 1713 - 1721. [Abstract] [Full Text]

				P. Mieyal, D. Fulton, J.C. McGiff, and J. Quilley NO-Independent Vasodilation to Acetylcholine in the Rat Isolated Kidney Utilizes a Charybdotoxin-Sensitive, Intermediate-Conductance Ca++-Activated K+ Channel J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 659 - 664. [Abstract] [Full Text]

				D. Fulton, J. C. McGiff, M. S. Wolin, P. Kaminski, and J. Quilley Evidence against a Cytochrome P450-Derived Reactive Oxygen Species as the Mediator of the Nitric Oxide-Independent Vasodilator Effect of Bradykinin in the Perfused Heart of the Rat J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 702 - 709. [Abstract] [Full Text]